Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells

Iijima,Kazutaka; Nakamura,Hajime; Takada,Kohichi; Hayasaka,Naotaka; Kubo,Tomohiro; Umeyama,Yui; Iyama,Satoshi; Miyanishi,Koji; Kobune,Masayoshi; Kato,Junji

doi:10.3892/ol.2021.12807

Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells

Authors:
- Kazutaka Iijima
- Hajime Nakamura
- Kohichi Takada
- Naotaka Hayasaka
- Tomohiro Kubo
- Yui Umeyama
- Satoshi Iyama
- Koji Miyanishi
- Masayoshi Kobune
- Junji Kato
View Affiliations

Affiliations: Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido 060-8543, Japan, Department of Hematology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido 060-8543, Japan
Published online on: May 24, 2021 https://doi.org/10.3892/ol.2021.12807
Article Number: 546
Copyright: © Iijima et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Six‑transmembrane epithelial antigen of the prostate 1 (STEAP1) has emerged as an ideal target in cancer therapeutics. However, the functions of STEAP1 in liver cancer remain unexplored. The current study aimed to characterize the biological roles of STEAP1 in liver cancer. STEAP1 expression was upregulated in tumor tissues, and high STEAP1 expression was associated with poor clinical outcomes in patients with liver cancer, according to several publicly available datasets. STEAP1 silencing using small interfering RNA inhibited cell proliferation and was accompanied by G1 arrest induced by the suppression of cyclin D1 and the promotion of p27. STEAP1 silencing suppressed c‑Myc expression, which was identified as a component in STEAP1 signal transduction by mining publicly available datasets and was then confirmed by PCR array. In conclusion, the knockdown of STEAP1 in liver cancer cell lines led to inhibition of cell proliferation involving G₁ arrest by suppressing c‑Myc. The present study provides a preclinical concept for STEAP1 as a druggable target in liver cancer.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al SHARP Investigators Study Group, : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
3	Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al RESORCE Investigators, : Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66. 2017. View Article : Google Scholar : PubMed/NCBI
4	Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
5	Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al IMbrave150 investigators, : Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
6	Stine ZE, Walton ZE, Altman BJ, Hsieh AL and Dang CV: MYC, metabolism, and cancer. Cancer Discov. 5:1024–1039. 2015. View Article : Google Scholar : PubMed/NCBI
7	Abou-Elella A, Gramlich T, Fritsch C and Gansler T: c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod Pathol. 9:95–98. 1996.PubMed/NCBI
8	Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, et al Cancer Genome Atlas Network, : Pan-cancer alterations of the MYC oncogene and its proximal network across the Cancer Genome Atlas. Cell Syst. 6:282–300.e2. 2018. View Article : Google Scholar : PubMed/NCBI
9	Duffy MJ and Crown J: Drugging ‘undruggable’ genes for cancer treatment: Are we making progress? Int J Cancer. 148:8–17. 2021. View Article : Google Scholar : PubMed/NCBI
10	Massó-Vallés D and Soucek L: Blocking Myc to treat cancer: Reflecting on two decades of omomyc. Cells. 9:8832020. View Article : Google Scholar
11	Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, et al: STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA. 96:14523–14528. 1999. View Article : Google Scholar : PubMed/NCBI
12	Moreaux J, Kassambara A, Hose D and Klein B: STEAP1 is overexpressed in cancers: A promising therapeutic target. Biochem Biophys Res Commun. 429:148–155. 2012. View Article : Google Scholar : PubMed/NCBI
13	Gomes IM, Maia CJ and Santos CR: STEAP proteins: From structure to applications in cancer therapy. Mol Cancer Res. 10:573–587. 2012. View Article : Google Scholar : PubMed/NCBI
14	Oosterheert W and Gros P: Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1). J Biol Chem. 295:9502–9512. 2020. View Article : Google Scholar : PubMed/NCBI
15	Nakamura H, Takada K, Arihara Y, Hayasaka N, Murase K, Iyama S, Kobune M, Miyanishi K and Kato J: Six-transmembrane epithelial antigen of the prostate 1 protects against increased oxidative stress via a nuclear erythroid 2-related factor pathway in colorectal cancer. Cancer Gene Ther. 26:313–322. 2019. View Article : Google Scholar : PubMed/NCBI
16	Menyhárt O, Nagy Á and Győrffy B: Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 5:1810062018. View Article : Google Scholar
17	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
18	Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V, Bertagnolli M, et al: BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 69:7577–7586. 2009. View Article : Google Scholar : PubMed/NCBI
19	Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao JJ, Mani M, Lemieux M, Carrasco DE, Ryan J, Horst D, et al: Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med. 4:148ra1172012. View Article : Google Scholar : PubMed/NCBI
20	Hayasaka N, Takada K, Nakamura H, Arihara Y, Kawano Y, Osuga T, Murase K, Kikuchi S, Iyama S, Emori M, et al: Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells. Sci Rep. 9:57592019. View Article : Google Scholar : PubMed/NCBI
21	Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, et al: Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 5:179ra432013. View Article : Google Scholar : PubMed/NCBI
22	Llovet JM, Montal R, Sia D and Finn RS: Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 15:599–616. 2018. View Article : Google Scholar : PubMed/NCBI
23	Danila DC, Szmulewitz RZ, Vaishampayan U, Higano CS, Baron AD, Gilbert HN, Brunstein F, Milojic-Blair M, Wang B, Kabbarah O, et al: Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer. J Clin Oncol. 37:3518–3527. 2019. View Article : Google Scholar : PubMed/NCBI
24	Dolezal JM, Wang H, Kulkarni S, Jackson L, Lu J, Ranganathan S, Goetzman ES, Bharathi SS, Beezhold K, Byersdorfer CA, et al: Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma. J Biol Chem. 292:10068–10086. 2017. View Article : Google Scholar : PubMed/NCBI
25	Zheng K, Cubero FJ and Nevzorova YA: c-MYC-making liver sick: Role of c-MYC in hepatic cell function, homeostasis and disease. Genes (Basel). 8:1232017. View Article : Google Scholar : PubMed/NCBI
26	Grunewald TG, Diebold I, Esposito I, Plehm S, Hauer K, Thiel U, da Silva-Buttkus P, Neff F, Unland R, Müller-Tidow C, et al: STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res. 10:52–65. 2012. View Article : Google Scholar : PubMed/NCBI